Maven Securities’s Ascendis Pharma A/S ASND Stock Holding History

Maven Securities’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$1.38M	–	793
2024 Q4	$1.38M	Sell	10,000 -40,000	-80%	-$5.26M	0.03%	360
2024 Q3	$7.47M	Buy	+50,000	New	+$6.75M	0.14%	115
2024 Q1	–	Sell	-3,000	Closed	-$378K	–	397
2023 Q4	$378K	Buy	+3,000	New	+$299K	0.01%	746
2017 Q4	–	Sell	-16,757	Closed	-$610K	–	44
2017 Q3	$610K	Buy	+16,757	New	+$481K	0.32%	27

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Maven Securities's ASND Position: Q1 2025 in Review

Maven Securities sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 10,000 shares — an estimated $1.38M sold.

Maven Securities first reported a position in ASND in Q3 2017 and held it in 4 quarters. The position peaked at $7.47M in Q3 2024. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

Maven Securities reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
Maven Securities sold 10,000 Ascendis Pharma A/S shares in Q1 2025, an estimated $1.38M.
Maven Securities first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 4 quarters.
Maven Securities's Ascendis Pharma A/S position peaked at $7.47M in Q3 2024.
244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.